{
    "abstract": "Background: Data on duration of protection against invasive meningococcal disease post-vaccination with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) are limited. We evaluated bactericidal activity persistence in adolescents/young adults up to 7.5 years post-primary vaccination with 4CMenB, and response to a booster dose compared with vaccine-na\u00efve controls. Methods: This open-label, multicenter study (NCT02446743) enrolled 15\u201324 year-old-previously vaccinated participants from Canada, Australia (group Primed_4y) 4 years post-priming with 4CMenB (2 doses; 0,1-month schedule), and Chile (Primed_7.5y) 7.5 years after priming with 4CMenB (2 doses; 0,1/0,2/0,6-month schedule) and vaccine-na\u00efve participants of similar age (Na\u00efve_4y and Na\u00efve_7.5y groups). Primed participants received a booster dose; vaccine-na\u00efve participants received 2 catch-up doses of 4CMenB, 1 month apart. We evaluated antibody persistence and immune responses using hSBA in terms of geometric mean titers and percentages of participants with hSBA titers \u22654, the kinetics of bactericidal activity post-booster (previously vaccinated) or post-2 doses (vaccine-na\u00efve), and safety. Results: Antibody levels declined at 4 (Primed_4y) and 7.5 (Primed_7.5y) years post-primary vaccination, but remained higher than in vaccine-na\u00efve participants at baseline (\u226444% vs \u2264 13% [fHbp]; \u226484% vs \u2264 24% [NadA]; \u226429% vs \u2264 14% [PorA]) for all vaccine antigens except NHBA (\u226481% vs \u2264 79%). One month post-booster and post-second dose, 93\u2013100% of primed and 79\u2013100% of vaccine-na\u00efve participants had hSBA titers \u22654 for all antigens. Kinetics of the antibody response were similar across groups with an early robust response observed 7 days post-booster/second dose. No vaccine-related serious adverse event was reported. Conclusion: For all antigens except NHBA, a higher proportion of primed participants had hSBA titers \u22654, at 4 and 7.5 years post-vaccination, compared with vaccine-na\u00efve participants. A more robust immune response after booster compared to a first dose in vaccine-na\u00efve individuals, showed effective priming in an adolescent/young adult population. No safety or new reactogenicity issues were identified.",
    "author_highlights": [
        {
            "endOffset": 19211,
            "sentence": "4\u20137.5 years post-2-dose 4CMenB primary series, 9\u201384% of subjects had hSBA titers \u22654 for \u22651 vaccine antigen.",
            "startOffset": 19104
        },
        {
            "endOffset": 19298,
            "sentence": "Antibody levels were higher in primed versus vaccine-na\u00efve individuals of similar age.",
            "startOffset": 19212
        },
        {
            "endOffset": 19380,
            "sentence": "Post-booster, 93\u2013100% of primed subjects had hSBA titers \u22654 against all antigens.",
            "startOffset": 19299
        },
        {
            "endOffset": 19464,
            "sentence": "Kinetics showed an early robust immune response at 7 days post-booster/second dose.",
            "startOffset": 19381
        },
        {
            "endOffset": 19549,
            "sentence": "The study raised no new safety concerns and overall, the vaccine was well-tolerated.",
            "startOffset": 19465
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Julie A.",
                    "initial": "J.A.",
                    "last": "Bettinger"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Jane",
                    "initial": "J.",
                    "last": "Jelfs"
                },
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "McIntyre"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Marco A.P.",
                    "initial": "M.A.P.",
                    "last": "S\u00e1fadi"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.12.032",
            "firstpage": "B26",
            "issn": "0264410X",
            "lastpage": "B36",
            "pmid": "22178525",
            "pub_year": 2012,
            "title": "The changing and dynamic epidemiology of meningococcal disease",
            "volume": "30"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Stephen I.",
                    "initial": "S.I.",
                    "last": "Pelton"
                }
            ],
            "doi": "10.1016/j.jadohealth.2016.04.012",
            "firstpage": "S3",
            "issn": "1054139X",
            "lastpage": "S11",
            "pmid": "27449148",
            "pub_year": 2016,
            "title": "The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines",
            "volume": "59"
        },
        "b0015": null,
        "b0020": {
            "authors": [
                {
                    "first": "Brett N.",
                    "initial": "B.N.",
                    "last": "Archer"
                },
                {
                    "first": "Clayton K.",
                    "initial": "C.K.",
                    "last": "Chiu"
                },
                {
                    "first": "Sanjay H.",
                    "initial": "S.H.",
                    "last": "Jayasinghe"
                },
                {
                    "first": "Peter C.",
                    "initial": "P.C.",
                    "last": "Richmond"
                },
                {
                    "first": "Jodie",
                    "initial": "J.",
                    "last": "McVernon"
                },
                {
                    "first": "Monica M.",
                    "initial": "M.M.",
                    "last": "Lahra"
                },
                {
                    "first": "Ross M.",
                    "initial": "R.M.",
                    "last": "Andrews"
                },
                {
                    "first": "Peter B.",
                    "initial": "P.B.",
                    "last": "McIntyre"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Nissen"
                },
                {
                    "first": "Sue",
                    "initial": "S.",
                    "last": "Campbell-Lloyd"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Peterson"
                },
                {
                    "first": "Ann",
                    "initial": "A.",
                    "last": "Koehler"
                },
                {
                    "first": "Julie",
                    "initial": "J.",
                    "last": "Leask"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.5694/mja16.01340",
            "firstpage": "382",
            "issn": "0025729X",
            "lastpage": "387",
            "pmid": "29092704",
            "pub_year": 2017,
            "title": "Epidemiology of invasive meningococcal b disease in Australia, 1999-2015: Priority populations for vaccination",
            "volume": "207"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "De Wals"
                },
                {
                    "first": "Genevi\u00e8ve",
                    "initial": "G.",
                    "last": "Deceuninck"
                },
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Lefebvre"
                },
                {
                    "first": "Raymond",
                    "initial": "R.",
                    "last": "Tsang"
                },
                {
                    "first": "Dennis",
                    "initial": "D.",
                    "last": "Law"
                },
                {
                    "first": "Gaston",
                    "initial": "G.",
                    "last": "De Serres"
                },
                {
                    "first": "Vladimir",
                    "initial": "V.",
                    "last": "Gilca"
                },
                {
                    "first": "Rodica",
                    "initial": "R.",
                    "last": "Gilca"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Boulianne"
                }
            ],
            "doi": "10.1093/cid/cix154",
            "firstpage": "1263",
            "issn": "10584838",
            "lastpage": "1267",
            "pmid": "28207068",
            "pub_year": 2017,
            "title": "Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada",
            "volume": "64"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Ana Bel\u00e9n",
                    "initial": "A.B.",
                    "last": "Ibarz-Pav\u00f3n"
                },
                {
                    "first": "Ana Paula",
                    "initial": "A.P.",
                    "last": "Lemos"
                },
                {
                    "first": "Maria Cecilia",
                    "initial": "M.C.",
                    "last": "Gorla"
                },
                {
                    "first": "Mabel",
                    "initial": "M.",
                    "last": "Regueira"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Corso"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Gagetti"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Efron"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Sorohuet"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Moscoloni"
                },
                {
                    "first": "P. R.",
                    "initial": "P.R.",
                    "last": "Rojas"
                },
                {
                    "first": "M. C.",
                    "initial": "M.C.",
                    "last": "Brandileone"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Maldonado"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Prat"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Seoane"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Araya"
                },
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Realpe"
                },
                {
                    "first": "O. M.",
                    "initial": "O.M.",
                    "last": "Sanabria"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Duarte"
                },
                {
                    "first": "G. C.",
                    "initial": "G.C.",
                    "last": "Chacon"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Llanes"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Tora\u00f1o"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Feliciano"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Guti\u00e9rrez"
                },
                {
                    "first": "C. P.",
                    "initial": "C.P.",
                    "last": "Almeida"
                },
                {
                    "first": "Y. N.",
                    "initial": "Y.N.",
                    "last": "San Mart\u00edn"
                },
                {
                    "first": "J. S.",
                    "initial": "J.S.",
                    "last": "Ch\u00f3ez"
                },
                {
                    "first": "Z. J.",
                    "initial": "Z.J.",
                    "last": "de Fuentes"
                },
                {
                    "first": "R. E.",
                    "initial": "R.E.",
                    "last": "Castillo"
                },
                {
                    "first": "M. V.",
                    "initial": "M.V.",
                    "last": "Terrazas"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Ech\u00e1niz-Avil\u00e9s"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Sandino"
                },
                {
                    "first": "A. O.",
                    "initial": "A.O.",
                    "last": "G\u00f3mez"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "de Quinzada"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "de Bola\u00f1os"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Fernandez"
                },
                {
                    "first": "G. A.",
                    "initial": "G.A.",
                    "last": "Chamorro Cortesi"
                },
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Le\u00f3n Ayala"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Kawabata"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Morales"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "S\u00e1nchez"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Pe\u00f1a"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Nurse-Lucas"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Francis"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Camou"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "P\u00e9rez-Giffoni"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Spadola"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Payares"
                },
                {
                    "first": "C. I.",
                    "initial": "C.I.",
                    "last": "Agudelo"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Casta\u00f1eda"
                },
                {
                    "first": "Jean Marc",
                    "initial": "J.M.",
                    "last": "Gabastou"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1371/journal.pone.0044102",
            "issn": "19326203",
            "pmid": "22952888",
            "pub_year": 2012,
            "title": "Laboratory-Based Surveillance of Neisseria meningitidis Isolates from Disease Cases in Latin American and Caribbean Countries, SIREVA II 2006-2010",
            "volume": "7"
        },
        "b0035": null,
        "b0040": null,
        "b0045": null,
        "b0050": {
            "authors": [
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Vega",
                    "initial": "V.",
                    "last": "Masignani"
                },
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                }
            ],
            "doi": "10.1080/14760584.2017.1308828",
            "firstpage": "433",
            "issn": "14760584",
            "lastpage": "451",
            "pmid": "28375029",
            "pub_year": 2017,
            "title": "Emerging experience with meningococcal serogroup B protein vaccines",
            "volume": "16"
        },
        "b0055": {
            "authors": [
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Donnelly"
                },
                {
                    "first": "Duccio",
                    "initial": "D.",
                    "last": "Medinia"
                },
                {
                    "first": "Giuseppe",
                    "initial": "G.",
                    "last": "Boccadifuoco"
                },
                {
                    "first": "Alessia",
                    "initial": "A.",
                    "last": "Biolchi"
                },
                {
                    "first": "Joel",
                    "initial": "J.",
                    "last": "Ward"
                },
                {
                    "first": "Carl",
                    "initial": "C.",
                    "last": "Frasch"
                },
                {
                    "first": "E. Richard",
                    "initial": "E.R.",
                    "last": "Moxon"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Stella"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "Comanducci"
                },
                {
                    "first": "Stefania",
                    "initial": "S.",
                    "last": "Bambini"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Muzzi"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Andrews"
                },
                {
                    "first": "Jie",
                    "initial": "J.",
                    "last": "Chene"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Santos"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Santini"
                },
                {
                    "first": "Philip",
                    "initial": "P.",
                    "last": "Boucher"
                },
                {
                    "first": "Davide",
                    "initial": "D.",
                    "last": "Serruto"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                },
                {
                    "first": "Marzia Monica",
                    "initial": "M.M.",
                    "last": "Giuliania"
                }
            ],
            "doi": "10.1073/pnas.1013758107",
            "firstpage": "19490",
            "issn": "00278424",
            "lastpage": "19495",
            "pub_year": 2010,
            "title": "Qualitative and quantitative assessment ofmeningococcal antigens to evaluate the potentialstrain coverage of protein-based vaccines",
            "volume": "107"
        },
        "b0060": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Goldschneider"
                },
                {
                    "first": "E. C.",
                    "initial": "E.C.",
                    "last": "Gotschlich"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Artenstein"
                }
            ],
            "doi": "10.1084/jem.129.6.1307",
            "firstpage": "1307",
            "issn": "00221007",
            "lastpage": "1326",
            "pmid": "4977280",
            "pub_year": 1969,
            "title": "Human immunity to the meningococcus. I. The role of humoral antibodies.",
            "volume": "129"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Marco Aur\u00e9lio",
                    "initial": "M.A.",
                    "last": "S\u00e1fadi"
                },
                {
                    "first": "Julie A.",
                    "initial": "J.A.",
                    "last": "Bettinger"
                },
                {
                    "first": "Gabriela Moreno",
                    "initial": "G.M.",
                    "last": "Maturana"
                },
                {
                    "first": "Godwin",
                    "initial": "G.",
                    "last": "Enwere"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1586/14760584.2015.979799",
            "firstpage": "505",
            "issn": "14760584",
            "lastpage": "517",
            "pmid": "25494168",
            "pub_year": 2015,
            "title": "Evolving meningococcal immunization strategies",
            "volume": "14"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Volker",
                    "initial": "V.",
                    "last": "Vetter"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "G\u00fclhan",
                    "initial": "G.",
                    "last": "Denizer"
                },
                {
                    "first": "Marco A.P.",
                    "initial": "M.A.P.",
                    "last": "S\u00e1fadi"
                },
                {
                    "first": "Sven Arne",
                    "initial": "S.A.",
                    "last": "Silfverdal"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Vyse"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1586/14760584.2016.1130628",
            "firstpage": "641",
            "issn": "14760584",
            "lastpage": "658",
            "pmid": "26651380",
            "pub_year": 2016,
            "title": "Routinely vaccinating adolescents against meningococcus: Targeting transmission & disease",
            "volume": "15"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Asad",
                    "initial": "A.",
                    "last": "Ali"
                },
                {
                    "first": "Rabab Zehra",
                    "initial": "R.Z.",
                    "last": "Jafri"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Messonnier"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Tevi-Benissan"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Durrheim"
                },
                {
                    "first": "Juhani",
                    "initial": "J.",
                    "last": "Eskola"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Fermon"
                },
                {
                    "first": "Keith P.",
                    "initial": "K.P.",
                    "last": "Klugman"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Samba",
                    "initial": "S.",
                    "last": "Sow"
                },
                {
                    "first": "Shao",
                    "initial": "S.",
                    "last": "Zhujun"
                },
                {
                    "first": "Zulfiqar",
                    "initial": "Z.",
                    "last": "Bhutta"
                },
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Abramson"
                }
            ],
            "doi": "10.1179/2047773214Y.0000000126",
            "firstpage": "11",
            "issn": "20477724",
            "lastpage": "20",
            "pmid": "24548156",
            "pub_year": 2014,
            "title": "Global practices of meningococcal vaccine use and impact on invasive disease",
            "volume": "108"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Mar\u00eda Elena",
                    "initial": "M.E.",
                    "last": "Santolaya"
                },
                {
                    "first": "Miguel L.",
                    "initial": "M.L.",
                    "last": "O'Ryan"
                },
                {
                    "first": "Mar\u00eda Teresa",
                    "initial": "M.T.",
                    "last": "Valenzuela"
                },
                {
                    "first": "Valeria",
                    "initial": "V.",
                    "last": "Prado"
                },
                {
                    "first": "Rodrigo",
                    "initial": "R.",
                    "last": "Vergara"
                },
                {
                    "first": "Alma",
                    "initial": "A.",
                    "last": "Mu\u00f1oz"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Gabriela",
                    "initial": "G.",
                    "last": "Gra\u00f1a"
                },
                {
                    "first": "Huajun",
                    "initial": "H.",
                    "last": "Wang"
                },
                {
                    "first": "Ralf",
                    "initial": "R.",
                    "last": "Clemens"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1016/S0140-6736(11)61713-3",
            "firstpage": "617",
            "issn": "01406736",
            "lastpage": "624",
            "pmid": "22260988",
            "pub_year": 2012,
            "title": "Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: A phase 2b/3 randomised, observer-blind, placebo-controlled study",
            "volume": "379"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Kirsten P.",
                    "initial": "K.P.",
                    "last": "Perrett"
                },
                {
                    "first": "Jodie",
                    "initial": "J.",
                    "last": "McVernon"
                },
                {
                    "first": "Peter C.",
                    "initial": "P.C.",
                    "last": "Richmond"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Marshall"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Nissen"
                },
                {
                    "first": "Allison",
                    "initial": "A.",
                    "last": "August"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Percell"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Nolan"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.06.103",
            "firstpage": "5217",
            "issn": "0264410X",
            "lastpage": "5224",
            "pmid": "26232542",
            "pub_year": 2015,
            "title": "Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study",
            "volume": "33"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Mar\u00eda Elena",
                    "initial": "M.E.",
                    "last": "Santolaya"
                },
                {
                    "first": "Miguel L.",
                    "initial": "M.L.",
                    "last": "O'Ryan"
                },
                {
                    "first": "Mar\u00eda Teresa",
                    "initial": "M.T.",
                    "last": "Valenzuela"
                },
                {
                    "first": "Valeria",
                    "initial": "V.",
                    "last": "Prado"
                },
                {
                    "first": "Rodrigo F.",
                    "initial": "R.F.",
                    "last": "Vergara"
                },
                {
                    "first": "Alma",
                    "initial": "A.",
                    "last": "Mu\u00f1oz"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Gabriela",
                    "initial": "G.",
                    "last": "Gra\u00f1a"
                },
                {
                    "first": "Huajun",
                    "initial": "H.",
                    "last": "Wang"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.4161/hv.25505",
            "firstpage": "2304",
            "issn": "21645515",
            "lastpage": "2310",
            "pmid": "23811804",
            "pub_year": 2013,
            "title": "Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine",
            "volume": "9"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Robert C.",
                    "initial": "R.C.",
                    "last": "Read"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Baxter"
                },
                {
                    "first": "David R.",
                    "initial": "D.R.",
                    "last": "Chadwick"
                },
                {
                    "first": "Saul N.",
                    "initial": "S.N.",
                    "last": "Faust"
                },
                {
                    "first": "Adam",
                    "initial": "A.",
                    "last": "Finn"
                },
                {
                    "first": "Stephen B.",
                    "initial": "S.B.",
                    "last": "Gordon"
                },
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                },
                {
                    "first": "David J.M.",
                    "initial": "D.J.M.",
                    "last": "Lewis"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                },
                {
                    "first": "David P.J.",
                    "initial": "D.P.J.",
                    "last": "Turner"
                },
                {
                    "first": "Rohit",
                    "initial": "R.",
                    "last": "Bazaz"
                },
                {
                    "first": "Amitava",
                    "initial": "A.",
                    "last": "Ganguli"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "Havelock"
                },
                {
                    "first": "Keith R.",
                    "initial": "K.R.",
                    "last": "Neal"
                },
                {
                    "first": "Ifeanyichukwu O.",
                    "initial": "I.O.",
                    "last": "Okike"
                },
                {
                    "first": "Begonia",
                    "initial": "B.",
                    "last": "Morales-Aza"
                },
                {
                    "first": "Kamlesh",
                    "initial": "K.",
                    "last": "Patel"
                },
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Williams"
                },
                {
                    "first": "Stefanie",
                    "initial": "S.",
                    "last": "Gilchrist"
                },
                {
                    "first": "Steve J.",
                    "initial": "S.J.",
                    "last": "Gray"
                },
                {
                    "first": "Martin C.J.",
                    "initial": "M.C.J.",
                    "last": "Maiden"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Huajun",
                    "initial": "H.",
                    "last": "Wang"
                },
                {
                    "first": "Maggie",
                    "initial": "M.",
                    "last": "McCarthy"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1016/S0140-6736(14)60842-4",
            "firstpage": "2123",
            "issn": "01406736",
            "lastpage": "2131",
            "pmid": "25145775",
            "pub_year": 2014,
            "title": "Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial",
            "volume": "384"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Robert C.",
                    "initial": "R.C.",
                    "last": "Read"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                },
                {
                    "first": "Xilian",
                    "initial": "X.",
                    "last": "Bai"
                },
                {
                    "first": "Kate",
                    "initial": "K.",
                    "last": "Nolan"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Rohit",
                    "initial": "R.",
                    "last": "Bazaz"
                },
                {
                    "first": "Annett",
                    "initial": "A.",
                    "last": "Kleinschmidt"
                },
                {
                    "first": "Maggie",
                    "initial": "M.",
                    "last": "McCarthy"
                },
                {
                    "first": "Huajun",
                    "initial": "H.",
                    "last": "Wang"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.11.071",
            "firstpage": "427",
            "issn": "0264410X",
            "lastpage": "434",
            "pmid": "27912986",
            "pub_year": 2017,
            "title": "A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine",
            "volume": "35"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Nolan"
                },
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "O'Ryan"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Wassil"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Abitbol"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.06.011",
            "firstpage": "4437",
            "issn": "0264410X",
            "lastpage": "4445",
            "pmid": "26187261",
            "pub_year": 2015,
            "title": "Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults",
            "volume": "33"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Sydel R.",
                    "initial": "S.R.",
                    "last": "Parikh"
                },
                {
                    "first": "Nick J.",
                    "initial": "N.J.",
                    "last": "Andrews"
                },
                {
                    "first": "Kazim",
                    "initial": "K.",
                    "last": "Beebeejaun"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Ribeiro"
                },
                {
                    "first": "Charlotte",
                    "initial": "C.",
                    "last": "Ward"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "White"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                }
            ],
            "doi": "10.1016/S0140-6736(16)31921-3",
            "firstpage": "2775",
            "issn": "01406736",
            "lastpage": "2782",
            "pmid": "28100432",
            "pub_year": 2016,
            "title": "Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study",
            "volume": "388"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Federico",
                    "initial": "F.",
                    "last": "Martin\u00f3n-Torres"
                },
                {
                    "first": "Alfonso",
                    "initial": "A.",
                    "last": "Carmona Martinez"
                },
                {
                    "first": "R\u00f3bert",
                    "initial": "R.",
                    "last": "Simk\u00f3"
                },
                {
                    "first": "Pilar",
                    "initial": "P.",
                    "last": "Infante Marquez"
                },
                {
                    "first": "Josep Lluis",
                    "initial": "J.L.",
                    "last": "Arimany"
                },
                {
                    "first": "Francisco",
                    "initial": "F.",
                    "last": "Gimenez-Sanchez"
                },
                {
                    "first": "Jos\u00e9 Antonio",
                    "initial": "J.A.",
                    "last": "Couceiro Gianzo"
                },
                {
                    "first": "\u00c9va",
                    "initial": "\u00c9.",
                    "last": "Kov\u00e1cs"
                },
                {
                    "first": "Pablo",
                    "initial": "P.",
                    "last": "Rojo"
                },
                {
                    "first": "Huajun",
                    "initial": "H.",
                    "last": "Wang"
                },
                {
                    "first": "Chiranjiwi",
                    "initial": "C.",
                    "last": "Bhusal"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                }
            ],
            "doi": "10.1016/j.jinf.2017.12.005",
            "firstpage": "258",
            "issn": "01634453",
            "lastpage": "269",
            "pmid": "29253560",
            "pub_year": 2018,
            "title": "Antibody persistence and booster responses 24\u201336 months after different 4CMenB vaccination schedules in infants and children: A randomised trial",
            "volume": "76"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Puiying A.",
                    "initial": "P.A.",
                    "last": "Mak"
                },
                {
                    "first": "George F.",
                    "initial": "G.F.",
                    "last": "Santos"
                },
                {
                    "first": "Kelly Anne",
                    "initial": "K.A.",
                    "last": "Masterman"
                },
                {
                    "first": "Jeff",
                    "initial": "J.",
                    "last": "Janes"
                },
                {
                    "first": "Bill",
                    "initial": "B.",
                    "last": "Wacknov"
                },
                {
                    "first": "Kay",
                    "initial": "K.",
                    "last": "Vienken"
                },
                {
                    "first": "Marzia",
                    "initial": "M.",
                    "last": "Giuliani"
                },
                {
                    "first": "Ann E.",
                    "initial": "A.E.",
                    "last": "Herman"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Cooke"
                },
                {
                    "first": "M. Lamine",
                    "initial": "M.L.",
                    "last": "Mbow"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Donnelly"
                }
            ],
            "doi": "10.1128/CVI.05028-11",
            "firstpage": "1252",
            "issn": "15566811",
            "lastpage": "1260",
            "pmid": "21715580",
            "pub_year": 2011,
            "title": "Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis",
            "volume": "18"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Orin S.",
                    "initial": "O.S.",
                    "last": "Levine"
                },
                {
                    "first": "Dan M.",
                    "initial": "D.M.",
                    "last": "Granofff"
                },
                {
                    "first": "Rosanna",
                    "initial": "R.",
                    "last": "Lagos"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Fritzell"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "doi": "10.1016/S0264-410X(96)00161-2",
            "firstpage": "325",
            "issn": "0264410X",
            "lastpage": "328",
            "pmid": "9139494",
            "pub_year": 1997,
            "title": "Factors associated with superior antibody responses to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age",
            "volume": "15"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Xin",
                    "initial": "X.",
                    "last": "Wang"
                },
                {
                    "first": "Amanda",
                    "initial": "A.",
                    "last": "Cohn"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "Comanducci"
                },
                {
                    "first": "Lubomira",
                    "initial": "L.",
                    "last": "Andrew"
                },
                {
                    "first": "Xin",
                    "initial": "X.",
                    "last": "Zhao"
                },
                {
                    "first": "Jessica R.",
                    "initial": "J.R.",
                    "last": "MacNeil"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Schmink"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Muzzi"
                },
                {
                    "first": "Stefania",
                    "initial": "S.",
                    "last": "Bambini"
                },
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Murphy"
                },
                {
                    "first": "Susan K.",
                    "initial": "S.K.",
                    "last": "Hoiseth"
                },
                {
                    "first": "Kathrin U.",
                    "initial": "K.U.",
                    "last": "Jansen"
                },
                {
                    "first": "Annaliesa S.",
                    "initial": "A.S.",
                    "last": "Anderson"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Leonard W.",
                    "initial": "L.W.",
                    "last": "Mayer"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.04.092",
            "firstpage": "4739",
            "issn": "0264410X",
            "lastpage": "4744",
            "pub_year": 2011,
            "title": "Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States",
            "volume": "29"
        },
        "b0135": {
            "authors": [
                {
                    "first": "E. D.G.",
                    "initial": "E.D.G.",
                    "last": "McIntosh"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Br\u00f6ker"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Wassil"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.07.019",
            "firstpage": "4414",
            "issn": "0264410X",
            "lastpage": "4421",
            "pmid": "26187262",
            "pub_year": 2015,
            "title": "Serum bactericidal antibody assays - The role of complement in infection and immunity",
            "volume": "33"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Giacomo",
                    "initial": "G.",
                    "last": "Frosi"
                },
                {
                    "first": "Alessia",
                    "initial": "A.",
                    "last": "Biolchi"
                },
                {
                    "first": "Morena Lo",
                    "initial": "M.L.",
                    "last": "Sapio"
                },
                {
                    "first": "Fabio",
                    "initial": "F.",
                    "last": "Rigat"
                },
                {
                    "first": "Stefanie",
                    "initial": "S.",
                    "last": "Gilchrist"
                },
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Lucidarme"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Marzia Monica",
                    "initial": "M.M.",
                    "last": "Giuliani"
                },
                {
                    "first": "Duccio",
                    "initial": "D.",
                    "last": "Medini"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.08.006",
            "firstpage": "4968",
            "issn": "0264410X",
            "lastpage": "4974",
            "pmid": "23954380",
            "pub_year": 2013,
            "title": "Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage",
            "volume": "31"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Federico",
                    "initial": "F.",
                    "last": "Martin\u00f3n-Torres"
                },
                {
                    "first": "Marco Aurelio P.",
                    "initial": "M.A.P.",
                    "last": "Safadi"
                },
                {
                    "first": "Alfonso Carmona",
                    "initial": "A.C.",
                    "last": "Martinez"
                },
                {
                    "first": "Pilar Infante",
                    "initial": "P.I.",
                    "last": "Marquez"
                },
                {
                    "first": "Juan Carlos Tejedor",
                    "initial": "J.C.T.",
                    "last": "Torres"
                },
                {
                    "first": "Lily Yin",
                    "initial": "L.Y.",
                    "last": "Weckx"
                },
                {
                    "first": "Edson Duarte",
                    "initial": "E.D.",
                    "last": "Moreira"
                },
                {
                    "first": "Ilhem",
                    "initial": "I.",
                    "last": "Mensi"
                },
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Calabresi"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.05.023",
            "firstpage": "3548",
            "issn": "0264410X",
            "lastpage": "3557",
            "pmid": "28533054",
            "pub_year": 2017,
            "title": "Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial",
            "volume": "35"
        }
    },
    "body_text": [
        {
            "endOffset": 22827,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 22826,
                    "startOffset": 22821
                },
                "b0010": {
                    "endOffset": 22826,
                    "startOffset": 22821
                }
            },
            "secId": "s0005",
            "sentence": "Widespread use of serogroup-specific vaccines against Neisseria meningitidis including serogroups A, C, W and Y has significantly decreased the incidence of invasive meningococcal disease (IMD) caused by these serogroups [1,2].",
            "startOffset": 22600,
            "title": "Introduction"
        },
        {
            "endOffset": 30679,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The protocol and the proposed informed consent form were reviewed and approved by the local Institutional Review Boards and/or an Ethics Committees before study start.",
            "startOffset": 30512,
            "title": "Study design and participants"
        },
        {
            "endOffset": 52508,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 52411,
                    "startOffset": 52404
                },
                "b0095": {
                    "endOffset": 52411,
                    "startOffset": 52404
                }
            },
            "secId": "s0085",
            "sentence": "Myalgia was the most common systemic reaction reported in other trials in adolescents and young adults [17,19], whereas in our study, headache and fatigue were reported as the most common systemic reactions.",
            "startOffset": 52301,
            "title": "Discussion"
        },
        {
            "endOffset": 37599,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Demographic and other characteristics at enrolment were balanced across previously vaccinated and vaccine-na\u00efve participants (Table 1).",
            "startOffset": 37464,
            "title": "Demographics"
        },
        {
            "endOffset": 50065,
            "parents": [],
            "secId": "s0085",
            "sentence": "The booster response was similar irrespective of the persistence period (4 or 7.5 years) post-primary vaccination in the parent studies.",
            "startOffset": 49929,
            "title": "Discussion"
        },
        {
            "endOffset": 50506,
            "parents": [],
            "secId": "s0085",
            "sentence": "Quantitative comparisons with other age-groups are not possible, due to the differences in vaccination schedules and more importantly, in immunity between infants/children and adolescents/adults.",
            "startOffset": 50311,
            "title": "Discussion"
        },
        {
            "endOffset": 36918,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "In addition, data were summarized by calculating the percentage of participants with a 4-fold rise post-vaccination and associated 2-sided 95% CIs, for each vaccine antigen.",
            "startOffset": 36745,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 52300,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 52299,
                    "startOffset": 52292
                },
                "b0085": {
                    "endOffset": 52299,
                    "startOffset": 52292
                }
            },
            "secId": "s0085",
            "sentence": "Pain was the most common local reaction, reported in \u226590% of the vaccinees, also comparable to similar studies [16,17].",
            "startOffset": 52181,
            "title": "Discussion"
        },
        {
            "endOffset": 25725,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 25536,
                    "startOffset": 25532
                }
            },
            "secId": "s0005",
            "sentence": "Some countries have introduced meningococcal vaccines in their routine infant and child vaccination programs to directly target the group most impacted by IMD [15]; however, due to the waning of meningococcal antibodies over time, these vaccines might not be able to offer protection through adolescence, when the second incidence peak usually emerges.",
            "startOffset": 25373,
            "title": "Introduction"
        },
        {
            "endOffset": 24784,
            "parents": [],
            "secId": "s0005",
            "sentence": "Clinical trial designs use laboratory assays to estimate antibody activity against antigen-specific meningococcal reference strains.",
            "startOffset": 24652,
            "title": "Introduction"
        },
        {
            "endOffset": 47807,
            "parents": [],
            "secId": "s0085",
            "sentence": "Nevertheless, the existence of such a correlation is supported by emerging real-life data on the impact of 4CMenB on MenB-caused IMD incidence.",
            "startOffset": 47664,
            "title": "Discussion"
        },
        {
            "endOffset": 25212,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 25211,
                    "startOffset": 25204
                },
                "b0070": {
                    "endOffset": 25211,
                    "startOffset": 25204
                }
            },
            "secId": "s0005",
            "sentence": "The target population for immunization against IMD varies worldwide, with available vaccines against 5 meningococcal serogroups, and the possibility to vaccinate different age groups [13,14].",
            "startOffset": 25021,
            "title": "Introduction"
        },
        {
            "endOffset": 43139,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "No death was reported in the study.",
            "startOffset": 43104,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 27166,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 27165,
                    "startOffset": 27161
                }
            },
            "secId": "s0005",
            "sentence": "Consistent results were obtained in the third study, which evaluated lot-to-lot consistency of 2 batches, immunogenicity and safety of 4CMenB in healthy Australian and Canadian adolescents [17].",
            "startOffset": 26972,
            "title": "Introduction"
        },
        {
            "endOffset": 23839,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 23824,
                    "startOffset": 23821
                },
                "b0045": {
                    "endOffset": 23838,
                    "startOffset": 23835
                }
            },
            "secId": "s0005",
            "sentence": "However in the last decade, MenB incidence has declined in these countries, while MenW incidence has increased in Australia [7] and Chile [9].",
            "startOffset": 23697,
            "title": "Introduction"
        },
        {
            "endOffset": 38659,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Moreover, adjusted hSBA GMTs for all antigens (except NHBA in the Primed_7.5y group) in previously-vaccinated participants were higher than in vaccine-na\u00efve participants (Table 2).",
            "startOffset": 38479,
            "title": "Antibody persistence"
        },
        {
            "endOffset": 37464,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "All, except 1 previously vaccinated participant, were included in the FAS for persistence; 271 primed participants and 250 na\u00efve participants completed the study (Supplementary Fig. 1).",
            "startOffset": 37279,
            "title": "Demographics"
        },
        {
            "endOffset": 53604,
            "parents": [],
            "secId": "s0090",
            "sentence": "Our study provides important information that will help to inform the choice of vaccination strategies to protect against IMD in adolescents and young adults.",
            "startOffset": 53446,
            "title": "Conclusion"
        },
        {
            "endOffset": 38137,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "In the Primed_7.5y participants, 7.5 years after 2-dose 4CMenB vaccination, hSBA titers \u22654 were observed in 44%, 84%, 29% and 81% of participants for fHbp, NadA, PorA and NHBA, respectively (Table 2).",
            "startOffset": 37937,
            "title": "Antibody persistence"
        },
        {
            "endOffset": 32128,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The 4CMenB vaccine (lot number JB148101) contains 50 \u00b5g each of recombinant proteins NHBA, NadA, and fHbp, adsorbed on aluminum hydroxide, 25 \u00b5g OMV expressing PorA P1.4 from the serogroup B strain NZ98/254, aluminum hydroxide, sodium chloride, histidine and sucrose.",
            "startOffset": 31861,
            "title": "Vaccines"
        },
        {
            "endOffset": 35110,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "For a sample size of 250 participants in the vaccine-na\u00efve group, the probability of detecting at least one participant with an AE occurring with a frequency of 1% was 92%.",
            "startOffset": 34938,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42192,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0075",
            "sentence": "One-month post-dose 2 (PPS Kinetics), the percentages increased to 100% for fHbp, 98% for NadA, 79% for PorA, and 95% for NHBA.",
            "startOffset": 42065,
            "title": "Immune responses in vaccine-na\u00efve participants"
        },
        {
            "endOffset": 37079,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The incidence of AEs per study group was tabulated with exact 95% CIs after each vaccination.",
            "startOffset": 36986,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 36558,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Additionally, the GMT ratio of the previously vaccinated group to the vaccine-na\u00efve group was computed.",
            "startOffset": 36455,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 48711,
            "parents": [],
            "secId": "s0085",
            "sentence": "The highest persistence was observed for NadA, followed by fHbp and PorA.",
            "startOffset": 48638,
            "title": "Discussion"
        },
        {
            "endOffset": 44286,
            "parents": [],
            "secId": "s0085",
            "sentence": "Importantly, the percentage of participants with hSBA titers \u22654 in previously vaccinated participants was higher than that of vaccine-na\u00efve participants against all vaccine antigens, except for NHBA, for which similarly high levels were observed in the 2 groups.",
            "startOffset": 44024,
            "title": "Discussion"
        },
        {
            "endOffset": 39526,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "hSBA GMTs were also higher in primed participants at 1 month post-booster dose compared to hSBA GMTs post-first dose in vaccine-na\u00efve participants.",
            "startOffset": 39379,
            "title": "Booster response"
        },
        {
            "endOffset": 42993,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "One SAE, appendicitis, was reported by 1 vaccine-na\u00efve participant post-first vaccine dose.",
            "startOffset": 42902,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 39859,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "At 1 month post-first dose, hSBA GMTs increased 2.4\u201325-fold in the Na\u00efve_4y group and 2.6\u201316-fold in the Na\u00efve_7.5y group, for all 4CMenB antigens (Supplementary Table 3).",
            "startOffset": 39688,
            "title": "Booster response"
        },
        {
            "endOffset": 53676,
            "parents": [],
            "secId": "s0095",
            "sentence": "Bexsero is a trademark of the GSK group of companies.",
            "startOffset": 53623,
            "title": "Trademark statement"
        },
        {
            "endOffset": 30777,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki.",
            "startOffset": 30679,
            "title": "Study design and participants"
        },
        {
            "endOffset": 33956,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Solicited local (injection site induration, swelling, erythema and pain) and systemic (fever [\u226538.0 \u00b0C], high fever [\u226539.5 \u00b0C], nausea, fatigue, myalgia, arthralgia, and headache) adverse events (AEs) were recorded using diary cards within 7 days post-vaccination and unsolicited AEs were reported within 30 days post-vaccination.",
            "startOffset": 33626,
            "title": "Safety assessment"
        },
        {
            "endOffset": 23390,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 23389,
                    "startOffset": 23386
                }
            },
            "secId": "s0005",
            "sentence": "IMD incidence varies globally, ranging between <0.5 cases/100,000 in North America to 10 cases/100,000 in the African meningitis belt [2].",
            "startOffset": 23252,
            "title": "Introduction"
        },
        {
            "endOffset": 34937,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "A target sample size of 250 participants in the vaccine-na\u00efve control group was determined to be large enough to reflect important variations in the population, but small enough to accommodate the operational constraints common to the extension studies and to allow for reliable (>90% probability) observations of common (\u22651%) AEs in the vaccine-na\u00efve participants.",
            "startOffset": 34572,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 30286,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The blood samples collected from previously vaccinated adolescents at 1 month post-vaccination in the primary studies were also used as control in this study.",
            "startOffset": 30128,
            "title": "Study design and participants"
        },
        {
            "endOffset": 24363,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 24362,
                    "startOffset": 24358
                }
            },
            "secId": "s0005",
            "sentence": "4CMenB contains 3 recombinant protein antigens (Neisseria adhesin A [NadA], Neisserial heparin binding antigen [NHBA] and factor H-binding protein [fHbp]) and outer membrane vesicles (OMV) expressing porin A protein (PorA), components that can provide broad protection against the majority of IMD caused by MenB strains [10].",
            "startOffset": 24038,
            "title": "Introduction"
        },
        {
            "endOffset": 51592,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 51411,
                    "startOffset": 51407
                }
            },
            "secId": "s0085",
            "sentence": "However, as observed in a previous study [16], first dose response suggests that 4CMenB could provide some protection within 4 weeks from vaccination, even in previously unvaccinated individuals, in case of epidemic outbreaks.",
            "startOffset": 51366,
            "title": "Discussion"
        },
        {
            "endOffset": 48637,
            "parents": [],
            "secId": "s0085",
            "sentence": "At 4 and 7.5 years post-primary vaccination, antibody levels declined, but were higher than in vaccine-na\u00efve participants, for all antigens except NHBA which was relatively high in both groups.",
            "startOffset": 48444,
            "title": "Discussion"
        },
        {
            "endOffset": 40704,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0070",
            "sentence": "In all participants, at 3 days post-booster or post-dose 2, hSBA GMTs remained similar to those before vaccination in the extension study.",
            "startOffset": 40566,
            "title": "Kinetics of antibody response"
        },
        {
            "endOffset": 30945,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A summary of the protocol is available at http://www.gsk-clinicalstudyregister.com (study ID 205218).",
            "startOffset": 30844,
            "title": "Study design and participants"
        },
        {
            "endOffset": 39378,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "In the primed groups, at 1 month post-booster dose, the percentages of participants with hSBA titer \u22654 were 93\u2013100% for all antigens; while the percentages of vaccine-na\u00efve participants with hSBA titers \u22654 post-first dose were significantly lower for all antigens except NHBA in the Primed_7.5y group, ranging between 41% and 92% (Supplementary Fig. 2; Supplementary Table 2).",
            "startOffset": 39002,
            "title": "Booster response"
        },
        {
            "endOffset": 34072,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The severity of the reported AEs and the relationship to the study vaccination were determined by the investigator.",
            "startOffset": 33957,
            "title": "Safety assessment"
        },
        {
            "endOffset": 41726,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0075",
            "sentence": "Post-dose 2 (PPS Kinetics), the percentages of participants with hSBA titer \u22654 increased to 99% and 100% for fHbp and NadA, 82% for PorA, and 91% for NHBA.",
            "startOffset": 41571,
            "title": "Immune responses in vaccine-na\u00efve participants"
        },
        {
            "endOffset": 32258,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "4CMenB suspension was prepared as a 0.5-mL dose and administered intramuscularly into the deltoid region of the non-dominant arm.",
            "startOffset": 32129,
            "title": "Vaccines"
        },
        {
            "endOffset": 42429,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Overall, almost all participants experienced at least 1 solicited AE post-vaccination.",
            "startOffset": 42343,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 24037,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 24036,
                    "startOffset": 24032
                }
            },
            "secId": "s0005",
            "sentence": "The development of a 4-component serogroup B meningococcal vaccine (4CMenB, Bexsero, GSK) and the MenB:fHBP vaccine (Trumenba, Pfizer) represents a significant recent advance in IMD prevention [10].",
            "startOffset": 23839,
            "title": "Introduction"
        },
        {
            "endOffset": 42064,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0075",
            "sentence": "In the FAS booster, pre-first dose, in the Na\u00efve_7.5y group, hSBA titers \u22654 were observed for 13%, 22%, 14% and 79% of participants for fHbp, NadA, PorA and NHBA, respectively; 1 month post-first dose they increased to 81%, 84%, 62% and 93%.",
            "startOffset": 41823,
            "title": "Immune responses in vaccine-na\u00efve participants"
        },
        {
            "endOffset": 26420,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 26419,
                    "startOffset": 26415
                }
            },
            "secId": "s0005",
            "sentence": "In September 2015, 4CMenB was introduced in the UK National Infant Immunization Program, where, 10 months after implementation, 4CMenB had halved the number of MenB IMD cases in vaccine-eligible infants [22].",
            "startOffset": 26212,
            "title": "Introduction"
        },
        {
            "endOffset": 40566,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0070",
            "sentence": "Overall, the percentage of vaccine-na\u00efve participants with hSBA \u22654 remained similar to pre-first dose values at 3 days post-dose 2, increased at 7 days post-dose 2, and remained unchanged at 1 month post-dose 2 for all antigens (Fig. 3).",
            "startOffset": 40329,
            "title": "Kinetics of antibody response"
        },
        {
            "endOffset": 45231,
            "parents": [],
            "secId": "s0085",
            "sentence": "It must also be noted that in our studies, immunogenicity was assessed at different laboratories during the parent and extension studies.",
            "startOffset": 45094,
            "title": "Discussion"
        },
        {
            "endOffset": 48444,
            "parents": [],
            "secId": "s0085",
            "sentence": "Long-term surveillance data and direct comparison to laboratory estimates of protection will add important information to the understanding of the true effect of vaccination on IMD.",
            "startOffset": 48263,
            "title": "Discussion"
        },
        {
            "endOffset": 47497,
            "parents": [],
            "secId": "s0085",
            "sentence": "Also, immunogenicity data in our study is generated from different populations, for which baseline characteristics, and therefore the elicited immune response to 4CMenB vaccination, can vary.",
            "startOffset": 47306,
            "title": "Discussion"
        },
        {
            "endOffset": 24519,
            "parents": [],
            "secId": "s0005",
            "sentence": "However, evaluating the efficacy of MenB vaccines is challenging, due to the low IMD incidence and therefore, to the difficulty in obtaining real-life data.",
            "startOffset": 24363,
            "title": "Introduction"
        },
        {
            "endOffset": 23252,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 23251,
                    "startOffset": 23248
                }
            },
            "secId": "s0005",
            "sentence": "In developed countries, overall IMD mortality rates can reach 10% and many survivors experience physical and neurological sequelae, despite treatment [2].",
            "startOffset": 23098,
            "title": "Introduction"
        },
        {
            "endOffset": 41514,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0075",
            "sentence": "In the FAS booster, pre-first dose, in the Na\u00efve_4y group, hSBA titers \u22654 were observed for 4%, 6%, 0% and 63% participants for fHbp, NadA, PorA and NHBA, respectively; 1 month post-first dose, they increased to 81%, 87%, 41% and 84%.",
            "startOffset": 41280,
            "title": "Immune responses in vaccine-na\u00efve participants"
        },
        {
            "endOffset": 28570,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a phase IIIb, open-label, controlled, multicenter study (NCT02446743), conducted between November 2015 and September 2016 in 12 centers in Australia, Canada and Chile.",
            "startOffset": 28394,
            "title": "Study design and participants"
        },
        {
            "endOffset": 49205,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 49204,
                    "startOffset": 49197
                },
                "b0145": {
                    "endOffset": 49204,
                    "startOffset": 49197
                }
            },
            "secId": "s0085",
            "sentence": "As NHBA, a surface-exposed lipoprotein, is highly conserved in all strains of pathogenic MenB and commensal Neisserial species tested so far, the higher initial titers may be due to exposure to circulating strains [10,29].",
            "startOffset": 48983,
            "title": "Discussion"
        },
        {
            "endOffset": 49928,
            "parents": [],
            "secId": "s0085",
            "sentence": "This suggests that despite a decline of bactericidal antibodies over time, previous vaccination with 4CMenB resulted in priming for immune memory and induced an anamnestic response in most individuals.",
            "startOffset": 49727,
            "title": "Discussion"
        },
        {
            "endOffset": 35936,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Immune response kinetics analyses were performed on the per-protocol set (PPS), comprising participants who correctly received the vaccine, had no protocol deviations and had evaluable immunogenicity results at each timepoint.",
            "startOffset": 35710,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 26758,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 26617,
                    "startOffset": 26613
                }
            },
            "secId": "s0005",
            "sentence": "In Chile [16], 2 doses administered 1, 2, or 6 months apart elicited protective immune responses in 98\u2013100% of adolescents up to 1 month post-second dose.",
            "startOffset": 26604,
            "title": "Introduction"
        },
        {
            "endOffset": 34571,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The sample size for the previously vaccinated participants was determined by the number of participants from the parent studies eligible to participate in this extension study (344 for the Primed_4y group and 529 for the Primed_7.5y group); a sample size of maximum 400 participants was planned.",
            "startOffset": 34276,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 47663,
            "parents": [],
            "secId": "s0085",
            "sentence": "The correlation between the currently accepted cut-off for protective antibody levels and effective protection against infection and IMD is also not clearly defined.",
            "startOffset": 47498,
            "title": "Discussion"
        },
        {
            "endOffset": 42750,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Pain was the most frequently reported solicited local AE (98%), while fatigue (\u226555%) and headache (\u226549%) were the most frequently reported solicited systemic AEs (Table 4).",
            "startOffset": 42578,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 50310,
            "parents": [],
            "secId": "s0085",
            "sentence": "Two doses of 4CMenB administered 1 month apart to 15\u201324-year-old vaccine-na\u00efve participants induced an overall robust antibody response for all vaccine antigens (79\u2013100%) with evidence of an early response from 1 month post-first dose (41\u201393%).",
            "startOffset": 50066,
            "title": "Discussion"
        },
        {
            "endOffset": 32760,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 32759,
                    "startOffset": 32755
                }
            },
            "secId": "s0030",
            "sentence": "The immune response was measured against antigen-specific N. meningitidis MenB indicator strains H44/76 (fHbp), 5/99 (NadA), NZ98/254 (PorA) and M10713 (NHBA); the assay was previously described in detail [24].",
            "startOffset": 32550,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 43375,
            "parents": [],
            "secId": "s0085",
            "sentence": "For the first time, we describe long-term antibody levels following 2 primary doses of 4CMenB in adolescents, measuring the percentages of individuals with protective antibody titers up to 7.5 years after primary vaccination.",
            "startOffset": 43150,
            "title": "Discussion"
        },
        {
            "endOffset": 44590,
            "parents": [],
            "secId": "s0085",
            "sentence": "The observed higher persistence of antibody levels against 4CMenB antigens in the Chilean cohort compared with that in the Australian and Canadian population, despite a longer follow-up period, is in line with the apparent mounting of a stronger immune response noted at 1 month post-primary vaccination.",
            "startOffset": 44286,
            "title": "Discussion"
        },
        {
            "endOffset": 27439,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 27438,
                    "startOffset": 27434
                }
            },
            "secId": "s0005",
            "sentence": "Similar results have been obtained in the infant population, with protective antibody levels for the different vaccine antigens ranging between 36% and 93% among infants at 24\u201336 months following vaccination according to different schedules in the first year of life [23].",
            "startOffset": 27167,
            "title": "Introduction"
        },
        {
            "endOffset": 51074,
            "parents": [],
            "secId": "s0085",
            "sentence": "In both groups, no significant increase in antibody levels was noted at day 3, but a robust response was observed at 7 days post-vaccination with 2 doses or a booster dose of 4CMenB, for all vaccine antigens.",
            "startOffset": 50866,
            "title": "Discussion"
        },
        {
            "endOffset": 29453,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A full list of inclusion and exclusion criteria is provided in Supplementary Text 1.",
            "startOffset": 29369,
            "title": "Study design and participants"
        },
        {
            "endOffset": 23573,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 23488,
                    "startOffset": 23485
                },
                "b0025": {
                    "endOffset": 23529,
                    "startOffset": 23526
                },
                "b0030": {
                    "endOffset": 23572,
                    "startOffset": 23569
                }
            },
            "secId": "s0005",
            "sentence": "In recent years, reported IMD incidence was 0.77 cases/100,000 population in Australia (2015) [4], 0.60 cases/100,000 in Canada (2014) [5] and 0.80 cases/100,000 in Chile (2015) [6].",
            "startOffset": 23391,
            "title": "Introduction"
        },
        {
            "endOffset": 47133,
            "parents": [],
            "secId": "s0085",
            "sentence": "Further studies are needed to accurately assess how laboratory data on antibody response to reference strains can be extrapolated to real-life impact on IMD.",
            "startOffset": 46976,
            "title": "Discussion"
        },
        {
            "endOffset": 25372,
            "parents": [],
            "secId": "s0005",
            "sentence": "In case of outbreak or exposure, the level of circulating antibody providing direct protection is an important consideration because of the rapid onset of IMD.",
            "startOffset": 25213,
            "title": "Introduction"
        },
        {
            "endOffset": 27839,
            "parents": [],
            "secId": "s0005",
            "sentence": "Although 4CMenB has been shown to be immunogenic and safe with protective circulating antibody levels up to 2 years, data on the duration of antibody levels after that period are limited.",
            "startOffset": 27652,
            "title": "Introduction"
        },
        {
            "endOffset": 49350,
            "parents": [],
            "secId": "s0085",
            "sentence": "Robust immunological responses were observed following booster vaccination at 4 years (94\u2013100%) and 7.5 years (93\u2013100%) post-primary vaccination.",
            "startOffset": 49205,
            "title": "Discussion"
        },
        {
            "endOffset": 49477,
            "parents": [],
            "secId": "s0085",
            "sentence": "A high proportion of vaccine-na\u00efve participants also achieved hSBA titers \u22654 post-administration of 2 vaccine doses (79\u2013100%).",
            "startOffset": 49351,
            "title": "Discussion"
        },
        {
            "endOffset": 42902,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Overall, unsolicited AEs were reported by 32% of previously vaccinated participants and 51% of vaccine-na\u00efve participants, 30 days post-any vaccination.",
            "startOffset": 42750,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 22934,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 22933,
                    "startOffset": 22928
                },
                "b0010": {
                    "endOffset": 22933,
                    "startOffset": 22928
                }
            },
            "secId": "s0005",
            "sentence": "N. meningitidis serogroup B (MenB) remains a major cause of outbreaks and endemic disease worldwide [1,2].",
            "startOffset": 22828,
            "title": "Introduction"
        },
        {
            "endOffset": 44709,
            "parents": [],
            "secId": "s0085",
            "sentence": "Moreover, higher pre-primary vaccination titers consequently resulted in higher immune response following vaccination.",
            "startOffset": 44591,
            "title": "Discussion"
        },
        {
            "endOffset": 41570,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0075",
            "sentence": "hSBA GMTs increased at least 2.4-fold for all antigens.",
            "startOffset": 41515,
            "title": "Immune responses in vaccine-na\u00efve participants"
        },
        {
            "endOffset": 52180,
            "parents": [],
            "secId": "s0085",
            "sentence": "Studies on 4CMenB that have enrolled participants of 10 years and older showed that the vaccine, albeit reactogenic, is well-tolerated with local and systemic reactions reported in similar proportions to those observed in this study.",
            "startOffset": 51947,
            "title": "Discussion"
        },
        {
            "endOffset": 48107,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 48106,
                    "startOffset": 48102
                },
                "b0140": {
                    "endOffset": 47932,
                    "startOffset": 47928
                }
            },
            "secId": "s0085",
            "sentence": "In the UK, a coverage of 88% across MenB strains is predicted by hSBA using pooled post-4-dose immunization infant sera [28], while a 2-dose field effectiveness of 83% against all MenB cases was derived from real-life data following the introduction of 4CMenB in the national immunization plan [22].",
            "startOffset": 47808,
            "title": "Discussion"
        },
        {
            "endOffset": 24651,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 24650,
                    "startOffset": 24646
                }
            },
            "secId": "s0005",
            "sentence": "Moreover, the variability of surface protein antigens in the sequence and level of expression with MenB strains is well known [11].",
            "startOffset": 24520,
            "title": "Introduction"
        },
        {
            "endOffset": 33457,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Testing was conducted in a blinded manner with respect to the study group, at the GSK Clinical Laboratory Sciences (Marburg, Germany) or at the Charles River Laboratories Edinburgh Ltd., UK.",
            "startOffset": 33267,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 28354,
            "parents": [],
            "secId": "s0005",
            "sentence": "Fig. 1 summarizes the research, clinical relevance and impact on the patient population.",
            "startOffset": 28266,
            "title": "Introduction"
        },
        {
            "endOffset": 48982,
            "parents": [],
            "secId": "s0085",
            "sentence": "For NHBA, the percentage of participants with hSBA titers \u22654 was comparable at 1 month post-primary vaccination and at 4 and 7.5 years and similar antibody levels were observed for previously primed and vaccine-na\u00efve participants before vaccination in the current study.",
            "startOffset": 48712,
            "title": "Discussion"
        },
        {
            "endOffset": 41823,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0075",
            "sentence": "hSBA GMTs increased 52-fold for fHbp; 204-fold for NadA; 11-fold for PorA and 3.2-fold for NHBA.",
            "startOffset": 41727,
            "title": "Immune responses in vaccine-na\u00efve participants"
        },
        {
            "endOffset": 32821,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Human plasma was used as the source of exogenous complement.",
            "startOffset": 32761,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 46039,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 46038,
                    "startOffset": 46034
                }
            },
            "secId": "s0085",
            "sentence": "In a study assessing immune responses to a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean participants, environmental factors were also associated with enhanced responses to vaccination, when compared with infants in the US or elsewhere [25].",
            "startOffset": 45757,
            "title": "Discussion"
        },
        {
            "endOffset": 23097,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 23096,
                    "startOffset": 23093
                }
            },
            "secId": "s0005",
            "sentence": "IMD incidence is highest in infants <1 year of age, but a second, smaller peak is reported in adolescents in whom meningococcal carriage predominantly occurs [3].",
            "startOffset": 22935,
            "title": "Introduction"
        },
        {
            "endOffset": 35188,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "No statistical hypotheses were associated with the immunogenicity objectives.",
            "startOffset": 35111,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 37936,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Four years after 2-dose 4CMenB vaccination, hSBA titers \u22654 in the Primed_4y group were observed in 30%, 84%, 9% and 75% of participants for fHbp, NadA, PorA and NHBA, respectively (Table 2).",
            "startOffset": 37746,
            "title": "Antibody persistence"
        },
        {
            "endOffset": 53926,
            "parents": [],
            "secId": "s0100",
            "sentence": "GlaxoSmithKline Biologicals SA took responsibility for all costs associated with the development and publishing of the present manuscript.",
            "startOffset": 53788,
            "title": "Funding"
        },
        {
            "endOffset": 53208,
            "parents": [],
            "secId": "s0090",
            "sentence": "Although antibody levels declined over time, a higher proportion of primed participants had hSBA titers \u22654, at 4 and 7.5 years post-primary vaccination, compared with vaccine-na\u00efve participants, except for NHBA, which was relatively high for vaccinated and unvaccinated individuals.",
            "startOffset": 52926,
            "title": "Conclusion"
        },
        {
            "endOffset": 36744,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The 95% CIs for the ratio of GMTs were constructed by exponentiating the difference of the least square means of the log-transformed titers and the lower and upper limits of the 95% CI.",
            "startOffset": 36559,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 38248,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "Similar observations were made for the percentage of participants with hSBA titers \u22655 (Supplementary table 1).",
            "startOffset": 38138,
            "title": "Antibody persistence"
        },
        {
            "endOffset": 29109,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "In the present study, primed individuals aged 15\u201324 years were invited to receive a third, booster dose of 4CMenB and were enrolled in the Primed_4y group (previously vaccinated participants from Canada and Australia) and Primed_7.5y group (previously vaccinated participants from Chile).",
            "startOffset": 28821,
            "title": "Study design and participants"
        },
        {
            "endOffset": 46622,
            "parents": [],
            "secId": "s0085",
            "sentence": "Immunogenicity was measured for each antigen separately, using representative N. meningitidis strains recognized only by antibodies induced by a single vaccine component.",
            "startOffset": 46452,
            "title": "Discussion"
        },
        {
            "endOffset": 45450,
            "parents": [],
            "secId": "s0085",
            "sentence": "Despite the consensus on the requirement of laboratory reporting to unify laboratory testing, laboratory assays remain subject to variations and interlaboratory comparisons should therefore be interpreted with caution.",
            "startOffset": 45232,
            "title": "Discussion"
        },
        {
            "endOffset": 45756,
            "parents": [],
            "secId": "s0085",
            "sentence": "Other factors, such as environmental and behavioral ones (for instance, exposure to daily smoking or household crowding) can also point to different exposure to the pathogen and potentially account for the difference observed in pre-vaccination titers between Chilean and Australian/Canadian participants.",
            "startOffset": 45451,
            "title": "Discussion"
        },
        {
            "endOffset": 44023,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 44022,
                    "startOffset": 44018
                }
            },
            "secId": "s0085",
            "sentence": "These levels were lower than those observed 18\u201323 months after vaccination with 2 doses of 4CMenB in Chile (75\u201395%) [18].",
            "startOffset": 43902,
            "title": "Discussion"
        },
        {
            "endOffset": 26211,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 26210,
                    "startOffset": 26203
                },
                "b0080": {
                    "endOffset": 25984,
                    "startOffset": 25977
                },
                "b0085": {
                    "endOffset": 25984,
                    "startOffset": 25977
                },
                "b0090": {
                    "endOffset": 25984,
                    "startOffset": 25977
                },
                "b0095": {
                    "endOffset": 25984,
                    "startOffset": 25977
                },
                "b0100": {
                    "endOffset": 25984,
                    "startOffset": 25977
                },
                "b0105": {
                    "endOffset": 26210,
                    "startOffset": 26203
                }
            },
            "secId": "s0005",
            "sentence": "4CMenB has been shown to be immunogenic and well-tolerated in adolescents [16\u201320] and is currently licensed in the United States as a 2-dose schedule in 10\u201325-year-olds, and for use from 2 months of age in Europe, Australia, Canada, and Latin America (Argentina, Brazil, Chile, Colombia and Uruguay) [10,21].",
            "startOffset": 25903,
            "title": "Introduction"
        },
        {
            "endOffset": 31850,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Secondary immunogenicity objectives were: (i) to assess the immune response 1 month post-booster in previously vaccinated participants, compared to the immune response at 1 month post-first dose in vaccine-na\u00efve participants; (ii) to assess and compare the response of the booster with the second dose administered to vaccine-na\u00efve participants, in terms of kinetics at 3, 7 and 30 days post-vaccination; (iii) to assess the immune response of 4CMenB administered to adolescent and young adult vaccine-na\u00efve participants, older than in the initial study (15\u201324 years of age), at 1 month post-dose 2.",
            "startOffset": 31251,
            "title": "Study objectives"
        },
        {
            "endOffset": 41229,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0070",
            "sentence": "Similar observations were made for the percentage of participants with hSBA titers \u22655 (Supplementary table 7).",
            "startOffset": 41119,
            "title": "Kinetics of antibody response"
        },
        {
            "endOffset": 51365,
            "parents": [],
            "secId": "s0085",
            "sentence": "For all antigens, hSBA titers were higher at 1 month post-booster than at 1 month post-second dose in vaccine-na\u00efve participants.",
            "startOffset": 51236,
            "title": "Discussion"
        },
        {
            "endOffset": 30127,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "These data served as a control for kinetics evaluation post-booster dose in previously vaccinated participants from whom 4 blood samples were taken at 4 and 7.5 years post-primary vaccination (pre-booster, 3, 7 and 30 days post-booster dose).",
            "startOffset": 29885,
            "title": "Study design and participants"
        },
        {
            "endOffset": 53787,
            "parents": [],
            "secId": "s0100",
            "sentence": "This study was funded by Novartis Vaccines and Diagnostics Inc., now part of the GSK group of companies.",
            "startOffset": 53683,
            "title": "Funding"
        },
        {
            "endOffset": 47305,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 47304,
                    "startOffset": 47300
                }
            },
            "secId": "s0085",
            "sentence": "The disadvantages and deriving limitations of the laboratory assays currently used for the evaluation of immune response to meningococcal vaccinations are well known [27].",
            "startOffset": 47134,
            "title": "Discussion"
        },
        {
            "endOffset": 51946,
            "parents": [],
            "secId": "s0085",
            "sentence": "In line with previous studies, most solicited local AEs and unsolicited AEs were mild to moderate in intensity, and resolved within a few days.",
            "startOffset": 51803,
            "title": "Discussion"
        },
        {
            "endOffset": 46975,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 46974,
                    "startOffset": 46970
                }
            },
            "secId": "s0085",
            "sentence": "For the many strains expressing more than one vaccine antigen, vaccine coverage may be maintained even if the expression of one antigen is below the threshold deemed predictive of killing [10].",
            "startOffset": 46782,
            "title": "Discussion"
        },
        {
            "endOffset": 30843,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This study is registered at www.clinicaltrials.gov (NCT02446743).",
            "startOffset": 30778,
            "title": "Study design and participants"
        },
        {
            "endOffset": 40329,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0070",
            "sentence": "The percentage of previously vaccinated participants with hSBA titers \u22654 remained similar to pre-booster against all strains at 3 days post-booster, increased at 7 days post-booster and remained unchanged or further increased at 1 month post-booster dose (Fig. 3).",
            "startOffset": 40065,
            "title": "Kinetics of antibody response"
        },
        {
            "endOffset": 38478,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "In both previously vaccinated groups, unadjusted hSBA GMTs decreased over time, but remained above pre-primary vaccination values at 4 and 7.5 years post-primary series, except for NHBA and PorA in the Primed_7.5y group (Table 3).",
            "startOffset": 38248,
            "title": "Antibody persistence"
        },
        {
            "endOffset": 40031,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "When analyzed by country, the percentages of participants with hSBA titers \u22654 and GMTs were similar between participants from Canada and Australia (Supplementary Table 4).",
            "startOffset": 39860,
            "title": "Booster response"
        },
        {
            "endOffset": 23696,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 23667,
                    "startOffset": 23662
                },
                "b0025": {
                    "endOffset": 23681,
                    "startOffset": 23676
                },
                "b0030": {
                    "endOffset": 23695,
                    "startOffset": 23692
                },
                "b0035": {
                    "endOffset": 23667,
                    "startOffset": 23662
                },
                "b0040": {
                    "endOffset": 23681,
                    "startOffset": 23676
                }
            },
            "secId": "s0005",
            "sentence": "Before 2010, MenB was responsible for >60% of the total IMD cases reported in Australia [4,7], Canada [5,8] and Chile [6].",
            "startOffset": 23574,
            "title": "Introduction"
        },
        {
            "endOffset": 28266,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 28196,
                    "startOffset": 28189
                },
                "b0085": {
                    "endOffset": 28196,
                    "startOffset": 28189
                }
            },
            "secId": "s0005",
            "sentence": "In addition we evaluated the response to a booster dose in participants from the parent studies [16,17], compared with primary vaccination in vaccine-na\u00efve healthy controls.",
            "startOffset": 28093,
            "title": "Introduction"
        },
        {
            "endOffset": 34253,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Medically-attended AEs (MAEs) and serious AEs (SAEs) were collected throughout the study by interviewing the participants and/or parents/guardians, and by reviewing medical records.",
            "startOffset": 34072,
            "title": "Safety assessment"
        },
        {
            "endOffset": 37278,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "A total of 531 individuals were enrolled, of whom 276 were previously vaccinated (Primed_4y: 145, Primed_7.5y: 131) and 255 were vaccine-na\u00efve (Na\u00efve_4y: 105, Na\u00efve_7.5y: 150).",
            "startOffset": 37102,
            "title": "Demographics"
        },
        {
            "endOffset": 46781,
            "parents": [],
            "secId": "s0085",
            "sentence": "Such assessments may underestimate overall immunogenicity since they do not account for the cooperative activity between different vaccine-induced antibodies.",
            "startOffset": 46623,
            "title": "Discussion"
        },
        {
            "endOffset": 39687,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0065",
            "sentence": "hSBA GMTs increased post-booster compared to pre-booster 4.7\u2013100-fold in the Primed_4y group and 5.2\u201364-fold in the Primed_7.5y group, for all vaccine antigens.",
            "startOffset": 39527,
            "title": "Booster response"
        },
        {
            "endOffset": 26603,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 26530,
                    "startOffset": 26523
                },
                "b0085": {
                    "endOffset": 26530,
                    "startOffset": 26523
                },
                "b0090": {
                    "endOffset": 26530,
                    "startOffset": 26523
                }
            },
            "secId": "s0005",
            "sentence": "The immunogenicity of 4CMenB in adolescents aged 11\u201317 years has been previously assessed in 3 studies [16\u201318] generating data for antibody persistence up to 2 years post-vaccination.",
            "startOffset": 26420,
            "title": "Introduction"
        },
        {
            "endOffset": 51235,
            "parents": [],
            "secId": "s0085",
            "sentence": "GMTs remained at high levels or further increased at 1 month post-booster (previously vaccinated participants) or post-second dose (vaccine-na\u00efve participants).",
            "startOffset": 51075,
            "title": "Discussion"
        },
        {
            "endOffset": 28092,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here, we assessed the persistence of bactericidal activity in adolescents and young adults, at approximately 4 and 7.5 years after a 2-dose primary series of 4CMenB compared with serum bactericidal activity in vaccine-na\u00efve participants of similar age.",
            "startOffset": 27840,
            "title": "Introduction"
        },
        {
            "endOffset": 46451,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 46450,
                    "startOffset": 46446
                }
            },
            "secId": "s0085",
            "sentence": "4CMenB is a combination of 4 antigens, selected to provide broad protection against the majority of MenB-related disease with a high proportion of MenB strains expressing 2 or more vaccine antigens [26].",
            "startOffset": 46248,
            "title": "Discussion"
        },
        {
            "endOffset": 48262,
            "parents": [],
            "secId": "s0085",
            "sentence": "Assessment of alternative measures, such as coverage against circulating strains, is also informative for estimations of vaccine impact and effectiveness.",
            "startOffset": 48108,
            "title": "Discussion"
        },
        {
            "endOffset": 51802,
            "parents": [],
            "secId": "s0085",
            "sentence": "The incidence of unsolicited AEs was similar between the previously vaccinated and vaccine-na\u00efve participants.",
            "startOffset": 51692,
            "title": "Discussion"
        },
        {
            "endOffset": 43103,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "This SAE was considered as unrelated to the study vaccine by the investigator and was resolved after 25 days.",
            "startOffset": 42994,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 31251,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary safety objective was to evaluate the safety and reactogenicity of 4CMenB in all participants.",
            "startOffset": 31146,
            "title": "Study objectives"
        },
        {
            "endOffset": 33266,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The percentage of participants with hSBA titer \u22655, \u22658 and \u226516 was also calculated; results for the latter 2 cut-offs are available on ClinicalTrials.gov.",
            "startOffset": 33113,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 45093,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 45092,
                    "startOffset": 45088
                }
            },
            "secId": "s0085",
            "sentence": "Of note, differences between pre-vaccination hSBA titers in UK university students and Chilean adolescents were previously observed, with baseline titers being higher in the case of the European trial [20].",
            "startOffset": 44887,
            "title": "Discussion"
        },
        {
            "endOffset": 25903,
            "parents": [],
            "secId": "s0005",
            "sentence": "Complete information on circulating antibody levels, booster response, and the effect of priming in all age groups is therefore of the outmost importance for vaccine scheduling.",
            "startOffset": 25726,
            "title": "Introduction"
        },
        {
            "endOffset": 46248,
            "parents": [],
            "secId": "s0085",
            "sentence": "However, a similar impact is unlikely in the case of 4CMenB vaccination, since to date, no association between environmental factors and immune responses has been observed in the course of any clinical trial.",
            "startOffset": 46040,
            "title": "Discussion"
        },
        {
            "endOffset": 52669,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 52586,
                    "startOffset": 52579
                },
                "b0085": {
                    "endOffset": 52586,
                    "startOffset": 52579
                }
            },
            "secId": "s0085",
            "sentence": "As expected for an adolescent population in light of previous studies [16,17], fever was not a common systemic reaction, and no participant reported high fever.",
            "startOffset": 52509,
            "title": "Discussion"
        },
        {
            "endOffset": 26971,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 26970,
                    "startOffset": 26966
                }
            },
            "secId": "s0005",
            "sentence": "Additionally, seroprotective activity for all vaccine-related antigens (hSBA titers above pre-specified values) was maintained over at least 18\u201323 months post-second dose in 77\u201394% of vaccinated adolescents [18].",
            "startOffset": 26759,
            "title": "Introduction"
        },
        {
            "endOffset": 43901,
            "parents": [],
            "secId": "s0085",
            "sentence": "hSBA titers \u22654 were retained by 9% (for PorA) to 84% (for NadA) of Australian and Canadian participants, up to 4 years, and by 29% (for PorA) to 84% (for NadA) of Chilean participants, up to 7.5 years post-primary vaccination with 4CMenB.",
            "startOffset": 43663,
            "title": "Discussion"
        },
        {
            "endOffset": 33112,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Data were summarized by calculating the percentages of participants with hSBA titer \u22654, hSBA geometric mean titers (GMTs), and geometric mean ratio (GMRs) of GMTs post-booster vs pre-booster (previously vaccinated participants) or post-dose 1 vs pre-first dose (vaccine-na\u00efve participants).",
            "startOffset": 32822,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 53445,
            "parents": [],
            "secId": "s0090",
            "sentence": "A more robust immune response was generally observed after a booster dose compared to a first dose in vaccine-na\u00efve population, demonstrating priming for immune memory and induction of an anamnestic response in a young adult population.",
            "startOffset": 53209,
            "title": "Conclusion"
        },
        {
            "endOffset": 29521,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Previously vaccinated participants were not randomized to treatment.",
            "startOffset": 29453,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29884,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Pre-first dose and post-dose 1 blood samples were also taken from vaccine-na\u00efve participants.",
            "startOffset": 29791,
            "title": "Study design and participants"
        },
        {
            "endOffset": 51691,
            "parents": [],
            "secId": "s0085",
            "sentence": "The vaccine was generally well-tolerated although solicited AEs were reported by most participants.",
            "startOffset": 51592,
            "title": "Discussion"
        },
        {
            "endOffset": 31145,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary immunogenicity objective was to assess the persistence of serum bactericidal activity at 4 and 7.5 years following primary series compared to vaccine-na\u00efve participants.",
            "startOffset": 30964,
            "title": "Study objectives"
        },
        {
            "endOffset": 52925,
            "parents": [],
            "secId": "s0090",
            "sentence": "Antibody levels against any one of the 4 4CMenB antigens remained above the protective threshold for 9\u201384% of adolescents, at 4\u20137.5 years after a 2-dose primary-vaccination series.",
            "startOffset": 52745,
            "title": "Conclusion"
        },
        {
            "endOffset": 37704,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The mean age of the enrolled participants was 19.7 years (standard deviation \u00b1 2.56) and 51% were males.",
            "startOffset": 37600,
            "title": "Demographics"
        },
        {
            "endOffset": 27651,
            "parents": [],
            "secId": "s0005",
            "sentence": "Due to the rapid onset, high case-mortality and severe sequelae of IMD, the quick mounting and long-term persistence of protective levels of circulating antibodies is key for the successful prevention of disease.",
            "startOffset": 27439,
            "title": "Introduction"
        },
        {
            "endOffset": 44886,
            "parents": [],
            "secId": "s0085",
            "sentence": "Several potential hypotheses for the differences between Chilean and Australian/Canadian adolescents can be formulated, which would require novel study designs to be addressed.",
            "startOffset": 44710,
            "title": "Discussion"
        },
        {
            "endOffset": 25021,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 24966,
                    "startOffset": 24962
                }
            },
            "secId": "s0005",
            "sentence": "The threshold used for MenB evaluation is a human complement serum bactericidal antibody assay (hSBA) titer of at least 4, accepted as a correlate of protection for serogroup C [12], and extended to the other N. meningitidis serogroups.",
            "startOffset": 24785,
            "title": "Introduction"
        },
        {
            "endOffset": 29369,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Two groups of vaccine-na\u00efve participants, Na\u00efve_4y (na\u00efve participants from Canada and Australia) and Na\u00efve_7.5y (na\u00efve participants from Chile) groups of similar age to Primed_4y and Primed_7.5y received 2 doses of 4CMenB, administered 1 month apart (Fig. 2).",
            "startOffset": 29109,
            "title": "Study design and participants"
        },
        {
            "endOffset": 43662,
            "parents": [],
            "secId": "s0085",
            "sentence": "The results of this study show that up to 7.5 years post-primary series, antibody levels generally declined for all vaccine antigens.",
            "startOffset": 43529,
            "title": "Discussion"
        },
        {
            "endOffset": 50696,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 50695,
                    "startOffset": 50691
                }
            },
            "secId": "s0085",
            "sentence": "However, despite declines in antibody levels following priming with 4CMenB, infants and young children also show robust immune responses following an additional booster dose of 4CMenB [23].",
            "startOffset": 50507,
            "title": "Discussion"
        },
        {
            "endOffset": 52734,
            "parents": [],
            "secId": "s0085",
            "sentence": "No new safety clinical concerns were reported during this study.",
            "startOffset": 52670,
            "title": "Discussion"
        },
        {
            "endOffset": 36454,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Unadjusted and adjusted GMTs and associated 95% CIs were computed for each group and for each vaccine antigen by exponentiating the least square means and the lower and upper limits of the 95% CIs of the log transformed titers or concentrations (base 10).",
            "startOffset": 36199,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 32550,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "A minimum of 10 mL of blood was drawn from each participant in the previously vaccinated groups at 3, 7 and 30 days post-booster dose and, for each participant in the vaccine-na\u00efve groups at day 30, 33 (or 37) and 60 post-first dose (Fig. 2, Supplementary Fig. 1).",
            "startOffset": 32286,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 33606,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The percentages of participants with 4-fold increase from pre-vaccination to post-vaccination for the vaccine-na\u00efve individuals were also summarized.",
            "startOffset": 33457,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 36985,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The safety analysis was performed on the \u2018as treated\u2019 analysis set.",
            "startOffset": 36918,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 35448,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Persistence analyses (primary immunogenicity objective) were performed on the full analysis set (FAS), including participants for whom evaluable immunogenicity results were available for at least 1 antigen, pre-booster/first vaccination in the extension study.",
            "startOffset": 35188,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 50865,
            "parents": [],
            "secId": "s0085",
            "sentence": "The study also investigated the kinetics of the antibody response post-booster in previously vaccinated participants, and post-second dose in vaccine-na\u00efve participants.",
            "startOffset": 50696,
            "title": "Discussion"
        },
        {
            "endOffset": 29790,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The first group had blood drawn at 3 and 30 days post-second dose; and the second group had blood drawn at 7 and 30 days post-second dose.",
            "startOffset": 29652,
            "title": "Study design and participants"
        },
        {
            "endOffset": 36198,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The percentages of participants with hSBA titer \u22654 and associated 2-sided 95% confidence intervals (CIs) were computed for all participants, as well as differences in percentages and 95% CIs between the previously vaccinated group and vaccine-na\u00efve participants.",
            "startOffset": 35936,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 40795,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0070",
            "sentence": "In general, GMTs increased at 7 days and 1 month post-vaccination (Supplementary Table 5).",
            "startOffset": 40705,
            "title": "Kinetics of antibody response"
        },
        {
            "endOffset": 41118,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0070",
            "sentence": "The proportion of participants with \u22654-fold increase in hSBA titers for previously vaccinated participants (post-booster vs pre-booster dose) ranged between 48% (NHBA) and 98% (fHbp and NadA); and for vaccine-na\u00efve participants (post-second dose vs pre-first dose) between 7% (NHBA) and 72% (NadA) (Supplementary Table 6).",
            "startOffset": 40796,
            "title": "Kinetics of antibody response"
        },
        {
            "endOffset": 28820,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 28819,
                    "startOffset": 28812
                },
                "b0085": {
                    "endOffset": 28819,
                    "startOffset": 28812
                }
            },
            "secId": "s0015",
            "sentence": "In the parent study, adolescents and young adults aged 11\u201317 years received a primary vaccination of 2 doses of 4CMenB approximately 4 (Canada and Australia, NCT01423084) and 7.5 years (Chile, NCT00661713) before participating in this study [16,17].",
            "startOffset": 28571,
            "title": "Study design and participants"
        },
        {
            "endOffset": 42577,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Within 7 days post-any vaccination, \u226597% of participants reported at least 1 solicited local AE and \u226575% reported at least 1 solicited systemic AE.",
            "startOffset": 42430,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 38981,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0060",
            "sentence": "GMRs (previously vaccinated participants compared to vaccine-na\u00efve participants) were 2.1 (fHbp), 20.0 (NadA), 1.3 (PorA) and 1.3 (NHBA) at 4 years post-vaccination in the Primed_4y group and 3.0 (fHbp), 14.0 (NadA), 1.7 (PorA) and 1.2 (NHBA) at 7.5 years post-vaccination in the Primed_7.5y group (Supplementary Table 2).",
            "startOffset": 38659,
            "title": "Antibody persistence"
        },
        {
            "endOffset": 43529,
            "parents": [],
            "secId": "s0085",
            "sentence": "Also, we describe the response to a booster dose in late adolescence and early adulthood, providing key information for decisions on booster vaccination.",
            "startOffset": 43376,
            "title": "Discussion"
        },
        {
            "endOffset": 30511,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from participants (or parents/legal guardians of participants under 18 years of age) prior to enrollment in the study, and assent was obtained from all participants under 18 years of age.",
            "startOffset": 30286,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35709,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Post-booster/first dose analyses were conducted in the FAS booster, which included participants who received a booster/first dose of 4CMenB and for whom evaluable immunogenicity results were available for at least 1 antigen, at 1 month post-booster/first dose.",
            "startOffset": 35449,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42315,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "s0075",
            "sentence": "hSBA GMTs increased 41-fold for fHbp; 123\u2013fold for NadA; 11-fold for PorA and 3.2-fold for NHBA, 1 month post-second dose.",
            "startOffset": 42193,
            "title": "Immune responses in vaccine-na\u00efve participants"
        },
        {
            "endOffset": 29651,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Vaccine-na\u00efve participants were randomized in a 1:1 ratio for differential blood drawing in order to determine antibody kinetics.",
            "startOffset": 29522,
            "title": "Study design and participants"
        },
        {
            "endOffset": 49726,
            "parents": [],
            "secId": "s0085",
            "sentence": "The administration of a 4CMenB booster dose in the previously vaccinated participants showed a more robust immune response with higher increase of hSBA titers, as compared to the response to a first dose in vaccine-na\u00efve participants of similar age.",
            "startOffset": 49477,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X19300283",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Terry",
                "initial": "T.",
                "last": "Nolan"
            },
            {
                "email": null,
                "first": "Maria Elena",
                "initial": "M.E.",
                "last": "Santolaya"
            },
            {
                "email": null,
                "first": "Ferdinandus",
                "initial": "F.",
                "last": "de Looze"
            },
            {
                "email": null,
                "first": "Helen",
                "initial": "H.",
                "last": "Marshall"
            },
            {
                "email": null,
                "first": "Peter",
                "initial": "P.",
                "last": "Richmond"
            },
            {
                "email": null,
                "first": "Sam",
                "initial": "S.",
                "last": "Henein"
            },
            {
                "email": null,
                "first": "Paul",
                "initial": "P.",
                "last": "Rheault"
            },
            {
                "email": null,
                "first": "Ken",
                "initial": "K.",
                "last": "Heaton"
            },
            {
                "email": null,
                "first": "Kirsten P.",
                "initial": "K.P.",
                "last": "Perrett"
            },
            {
                "email": null,
                "first": "Hartley",
                "initial": "H.",
                "last": "Garfield"
            },
            {
                "email": null,
                "first": "Anil",
                "initial": "A.",
                "last": "Gupta"
            },
            {
                "email": null,
                "first": "Murdo",
                "initial": "M.",
                "last": "Ferguson"
            },
            {
                "email": null,
                "first": "Diego",
                "initial": "D.",
                "last": "D'Agostino"
            },
            {
                "email": null,
                "first": "Daniela",
                "initial": "D.",
                "last": "Toneatto"
            },
            {
                "email": "moryan@med.uchile.cl",
                "first": "Miguel",
                "initial": "M.",
                "last": "O'Ryan"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.12.059",
        "firstpage": "1209",
        "issn": "0264410X",
        "keywords": [
            "4-component serogroup B meningococcal vaccine",
            "Adolescents",
            "Immunogenicity",
            "Kinetics",
            "Persistence"
        ],
        "lastpage": "1218",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine"
    }
}